Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers. Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise …

78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing Cancer Treatment Breakthroughs Carcinotech provides comprehensive solid tumor research services to advance drug development and enhance personalized therapy decisions. At the heart of its offerings is the proprietary Carcino3DTM bioprinting technology, which creates assay-ready, 3D tumors derived from patient biopsies. This innovative, translational approach delivers a predictive in vitro model, generating critical insights into therapeutic efficacy, and treatment optimization. Cancer research, 3D bioprinting , Cancer microenvironment, drug testing, oncology, assay services, oncology pre-clinical services, solid tumours, solid tumors, tumour microenvironment, tumor microenvironment, early phase drug development, and early drug discovery

274 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

The company that believes everyone should benefit directly from compelling scientific research. Elysium Health’s mission is to solve the biggest challenges in health with science, to help people live healthier for longer. Elysium works directly with top scientists, clinicians and health professionals around the world to translate advances in science and technology into innovative health products that work. Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Throughout this process, Elysium’s focus is to develop compounds found in nature that allow people …

52 similar entities Type: Startup Activities: biotech deeptech

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer …

115 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Translational Pharmacology and Preclinical Services for Oncology, Inflammation, and Radiopharmaceutical Research Oncodesign Services supports biopharma and biotechnology teams navigating critical preclinical decisions as programs progress toward the clinic. At this stage, generating data alone is not enough; what matters is whether the evidence genuinely supports the next step forward. We are a preclinical contract research organization specializing in advanced development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases. Our work is focused on the translational phase of drug development, where scientific rigor, careful study design, and clear interpretation are essential to support confident progression toward IND and …

83 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing a first-in-class treatment for advanced renal cancer Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.

76 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Kura Oncology is a commercial-stage biopharmaceutical company committed to discovering and developing innovative precision medicines to help patients with cancer lead better, longer lives. Through our deep understanding of cancer biology and decades of experience in precision oncology, we are studying the underlying causes of treatment resistance. This enables us to design smart combination regimens with other cancer therapies to target tumors from multiple directions, with the goal of improving long-term clinical benefit. Kura developed and is commercializing KOMZIFTITM (ziftomenib), the …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

219 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Engineering the future of aging medicine. We are advancing small molecule therapeutics for age-related diseases. Our platform enables precise, dynamic control of biological targets and pathways, generating high-fidelity datasets that, combined with advanced AI, unlock systematic exploration of previously inaccessible chemical space. At its core are our ultra-large, in-house aging datasets, which provide a rich foundation for target identification and therapeutic discovery. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, rejuvenation, molecular biology, novel therapeutics, therapeutics, and small molecules

178 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Developing selective inhibitors of CTPS1 for patients with cancer and auto-immune diseases Step Pharma is the world leader in the discovery and development of inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma’s lead program dencatistat (STP938) is a first in class, potent, selective, oral inhibitor of CTPS1 with demonstrated anti-tumor activity. Dencatistat entered clinical development in 2022 in a PhI/II study for the treatment of relapsed and refractory T-cell and B-cell lymphoma. More recently a solid tumour study was started focused on ovarian cancer using the concept of synthetic lethality and …

72 similar entities Tags: FrenchTech120 Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients. Biotechnology, Biotherapeutics, Cell …

201 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Drugging the Undruggable® PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using …

240 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

372 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering …

197 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery. We use exquisitely tuned assays to deliver accurate, robust and reproducible kinetic data of the highest quality that enhances the identification of compounds with the greatest therapeutic potential. The insight …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Accelerating biomedical research by connecting biopharmas with the right preclinical cancer models and CRO partners Repositive is committed to accelerating the development of precision cancer therapies to the clinic by working with biopharmas and Contract Research Organisations (CROs) to improve the predictivity of pre-clinical cancer research. Through its Cancer Models Scout service, Repositive is helping biopharmas to optimise their pre-clinical cancer projects by identifying the most suitable cancer models for their requirements from its world-leading database of over 8000 models, as well as via outreach to an extended network of CRO contacts. Repositive works to connect researchers with the right …

130 similar entities Type: Startup Activities: biotech it services deeptech Technologies: Synthetic Biology

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and …

402 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Changing the future of cancer care by accurately predicting patient response to therapies before treatment begins Kiyatec is disrupting cancer care by accurately predicting patient–specific response and non–response before treatment begins. We utilize the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies in our CLIA-certified and research laboratories. Our goal is to enable physicians to isolate only the effective treatments for their patients as quickly as possible - making true personalized medicine a reality. Our approach has been validated through engagements with leading cancer hospitals, multiple top 10 pharmaceutical companies and …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We develop treatments to give hope back to patients. Tratamientos que devuelven la esperanza a los pacientes. We are a biotechnology company that develops effective and safe therapeutic treatments for cancer with the purpose of restoring hope to patients who have no other option. We have been studying cancer and especially its relationship with inflammation for more than 7 years. Somos una empresa biotecnológica que desarrolla tratamientos terapéuticos eficaces y seguros contra el cáncer con el propósito de devolver la esperanza a pacientes que no tienen otra opción. Llevamos más de 7 años estudiando el cáncer y especialmente su relación …

96 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Biotech specialized in the design of new medicine. Let's connect to know more about us ! At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Sea to Pharmacy Perha Pharmaceuticals is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors and developing them up to proof-of-concept in man. Perha Pharma focuses its research on two main diseases: cognitive disorders associated with Down syndrome (DS) and Alzheimer’s disease (AD), and hearing loss (HL) induced by ototoxic products. The first proof-of-concept in man should be achieved in both pathologies through niche indications: cognitive deficits in DS and hearing loss induced by cis-platin or aminoglycoside antibiotics. Perha Pharma was co-founded in April 2019 by Dr Laurent MEIJER, Chairman & CSO, former distinguished Director …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At e-miRgency, we're pioneers in harnessing miRNA technology to revolutionize cancer diagnostics and patient care. ​ Transforming Cancer Detection Through miRNA Technology ​In the battle against cancer, early detection is the key to saving lives. Yet, for far too long, the limitations of existing detection methods have left us with critical challenges. Traditional approaches are often invasive, costly, and can miss the mark when it comes to detecting cancer at its earliest and most treatable stages. Why miRNAs Matter: This is where miRNAs step into the spotlight. MicroRNAs, abbreviated as miRNAs, are tiny but powerful molecules found within our cells. …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production …

76 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Sharp understanding of the hardest things At Sagacity Health, we discover new horizons in oncology by merging Agentic AI with Biotech to decode the secret world inside tumors - turning unseen ecosystems into the next frontier of precision therapeutics. Our main objective is to bridge groundbreaking science, clinical partnerships, and industrial-scale innovation to bring first-in-class therapies from lab to patient. This is not just drug development; it is a paradigm shift in how we fight cancer.

265 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Basic and translational research on cancer, immunity, metabolism and chronic diseases, toward precision medicine. Basic and translational research on cancer, immunity, metabolism and chronic diseases, to make precision medicine a reality.

59 similar entities Type: SMB Activities: biotech deeptech

Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, …

196 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Dolinnov, we transform chronic pain care with innovative Lipid ASO therapies, offering hope for complex conditions. Dolinnov is a french preclinical research company dedicated to advancing solutions for chronic pain management, driven by a passion for science and innovation. Our mission is to improve patients’ lives by delivering cutting-edge solutions for severe and unbearable conditions. Leveraging our proprietary conjugated L-ASO technology, we design targeted, effective, and safer therapies. This breakthrough approach directly addresses the root causes of pain through precise molecular interventions, providing hope to those enduring chemotherapy-induced pain and other challenging conditions. Biotechnology, Pain Management, ASO Therapy, and …

82 similar entities Type: Startup Activities: deeptech biotech healthtech

Targeting the Source. Transforming the Outcome. We develop miRNA-based therapies that address the root causes of neurological diseases. This goes far beyond the limitations of current treatment options, which only manage individual symptoms.

157 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A tissue-level multidisciplinary approach to curing Endometriosis. Our mission is to cure endometriosis. We are a team of interdisciplinary scientists creating a new model in women's health research centred around an in depth understanding of tissue-level disease processes. We are committed to improving the quality of life of women by providing a new model for therapeutic discovery. We sit at the interface between tissue biology, computation and laboratory disease modelling.

64 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

We do the research, so that no more lives are cut short from breast cancer | #nomorelivescutshort Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand with a commitment to exploring and finding better treatments for people affected by breast cancer through clinical trials research. Formerly known as the Australia & New Zealand Breast Cancer Trials Group and our fundraising department, the Breast Cancer Institute of Australia, we are on a mission for people affected by breast cancer to live better, to live longer and to never die from breast …

48 similar entities Type: SMB Activities: biotech deeptech

Beyond Inhibition. Reprogramming Cancer Control. Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors. Founded in 2016, the company is dedicated to advancing transformative therapies by harnessing next-generation science, disciplined development, and a commitment to clinical impact. Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet need.

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our …

222 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Stellate Therapeutics develops innovative microbiome-derived small molecules to treat neurodegenerative diseases. Stellate Therapeutics is a pre-clinical stage start-up company developing innovative microbiome-derived small molecules to treat neurodegenerative diseases. We utilize the microbiome for our drug portfolio and our research focuses on the gut-brain axis. Due to millions of years of co-evolution, complex metabolic interactions exist between humans and their gut bacteria and Stellate has uncovered a unique set of metabolites that are produced by the microbiome and are involved in the maintenance of health. Our first drug will be a treatment for Parkinson’s disease.

74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NuCana is a clinical-stage biopharmaceutical company developing an expansive portfolio of new medicines to treat cancer. NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome …

83 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

284 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Empower Cells In Vivo to Fight Diseases. EsoBiotec is a biotechnology company developing innovative therapeutics to fight cancer. Our mission is to empower the human body to tackle cancer by bringing in vivo engineering of cells to patients. We aim to develop cost-effective and off-the-shelf therapeutics and providing state-of-the-art cell therapies to maximise accessibility. Our disruptive approach holds the potential to transform the current standard of cell and gene therapies for cancer treatment. Gene therapy, Biotechnology, Oncology, Cell therapy, Cancer, in vivo engineering, virology, and Immunology

216 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Incipiam means ”I will begin” and that is where we believe we are – at the forefront of a paradigm shift in metabolic disease treatment. Most treatment options currently in development for metabolic disease focus on reduction of energy intake. While this is important, we see a new era of weight loss therapeutics emerging, where reduction in energy intake is insufficient to advance both the understanding of metabolic disease but also to drive development of novel treatments. At Incipiam Pharma, we're pioneering the next wave of weight loss therapeutics, targeting energy expenditure to revolutionize treatment for those living with obesity …

58 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways. Jalon Therapeutics aims to develop innovative therapies that inactivate yet untargeted vital tumor signaling pathways. Our mission is to develop medicines that will transform the lives of people fighting cancer. For that purpose, we leverage our deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. This mechanism, defined as “non-oncogene addiction” (NOA), offers potential novel, safer and more effective therapeutic strategies. Jalon Therapeutics is rooted in pioneering fundamental research and clinical investigations from INSERM laboratories …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com …

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives by accelerating innovation in cardiometabolic health Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. …

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Translating genetic discoveries into safe and effective treatments. Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with …

368 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Breaking resistance barriers in oncology. ReACT Therapeutics is a French biotech company working to restore the effectiveness of cancer treatments and improve the quality of care provided to patients. Created in January 2023 in Grenoble, ReACT Therapeutics aims to develop a new class of molecules capable of blocking the phenomena of multi-resistance responsible for therapeutic failures. ➡️ Our mission: Work for and with patients to restore the effectiveness of their cancer treatments and improve the quality of their care. ➡️ Our goal: Develop a new class of molecules capable of blocking multi-resistance phenomena in oncology. The result of 15 years …

104 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Targeting cellular senescence to extend human healthspan at old age and to counteract late stage cancer Cleara is a biopharmaceutical R&D company dedicated to discovery and development of therapies against cancer and chronic diseases through selective elimination of subtypes of cellular senescence. Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative and proprietary platform technology to design and optimize (peptide-based) therapeutics that exploit their weak spots for safe and selective clearance. Cleara’s lead FOXO4 program is focused on generation of disruptive and proprietary technology against “scarred” cellular senescence for …

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Biopharmaceutical company performing discovery, rational design and initial clinical development of new MLT-based drugs. Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba. Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Harnessing the power of chemical novelty, diversity and 3-dimensionality to develop innovative small molecule drugs PharmEnable is a biopharmaceutical company utilizing AI to discover effective small-molecule medicines for disease targets that are inaccessible to antibodies. With our proprietary AI-enabled drug discovery platform, chemSEEK, we explore new chemical spaces and discover novel small molecules with antibody-like specificity and selectivity. We are developing a pipeline of wholly owned therapeutics with initial focus on oncology and neurology. We also engage in drug discovery partnerships across a range of disease areas where accessing the target poses a significant challenge. PharmEnable is based in Cambridge, …

92 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

An innovative drug discovery technology Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure …

283 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering therapeutics directly into the cytosol of tumor cells to unlock previously undruggable cancer targets iDEL Therapeutics is a biotechnology company developing a pioneering drug delivery platform designed to transport therapeutic payloads directly into the cytosol of tumor cells. Our proprietary synthetic shuttle technology leverages a unique pan-cancer uptake mechanism that enables high intracellular drug exposure and sustained tumor retention while evading endosomal trapping. The platform is compatible with both small and large molecules, including nanobody-based therapeutics targeting oncogenes and tumor-directed cytotoxic payloads. iDEL Therapeutics is advancing a pipeline of innovative cancer therapies designed to unlock historically undruggable intracellular targets. …

114 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Array BioPharma Inc. (NASDAQ: ARRY) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics). We have locations in Boulder, CO; Cambridge, MA; and Morrisville, NC. Small molecule drug discovery and development., oncology, biotechnology, melanoma, and colorectal cancer

181 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We want to improve the way people age Topadur Pharma AG is a Swiss biopharmaceutical scale-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

616 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell …

93 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active …

128 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

630 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

From Nature to market Who we are : Greenpharma is a CRO SME of 12 people, specialised in natural compound studies for cosmetic, food and pharmaceutical industries. Built around an innovative technological platform, Greenpharma succeeded to gather expertise in wide and complementary fields such as chemoinformatic, pharmacognosy, medicinal & analytical chemistry, pilot scale extraction and formulation. This has led to a unique know-how in natural compound & extract selection, extract purification, metabolite measurement, homology modelling, virtual screening (e.g. SelnergyTM), lead optimisation, ADMET prediction and database building. Greenpharma approach has led to several patents on bioactive (natural or synthetic) molecules and …

72 similar entities Type: SMB Activities: biotech deeptech Technologies: Bio sourced materials

Building on our impossible firsts, we can change the course of human health. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. RNA-targeted medicines and RNA-targeted …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

AI-powered therapeutics for treatment-resistant cancer Synamics Therapeutics is an AI-driven therapeutics company developing smarter therapies for treatment-resistant cancer. Cancer evolves. Tumors adapt, mutate, and escape treatment, leaving patients with fewer options and drug developers facing costly cycles of resistance, redesign, and clinical failure. Synamics is building Dynaptive, an evolution-aware drug discovery platform designed to predict cancer’s next resistance moves and support the design of more durable therapies from the start. Our approach integrates artificial intelligence, cancer biology, structural modeling, and therapeutic design to identify vulnerabilities in resistant disease and generate drug candidates built for the realities of tumor evolution. We …

82 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Stopping non-genetic cancer drug resistance as it emerges TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit. Drug Discovery, Drug Development, Cancer Drug …

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical needs in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. Our pipeline is both in Human and Veterinary medicine. Our drugs are …

370 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We develop new selective and potent drugs for intrinsically disordered targets. Nuage Therapeutics is a biotech company focused on developing small molecule inhibitors of oncogenic transcription factors. The company has a particular focus on drugging cell lineage-specific transcription factors that are known cancer dependency genes. Built on a deep understanding of transcriptional regulation and the biophysics of intrinsically-disordered proteins (IDPs), Nuage has developed technologies that enable the ‘capture’ of IDPs in higher-order, self-assembled states that present binding pockets that render these proteins amenable to small molecule drug discovery. This represents a game-changing advance that has led to the identification of …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing next generation DDR targeting therapies Nodus oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response. Supported by most recent scientific advances, we are developing the next wave of cancer therapeutics in the DNA damage response (DDR) area. Founded by Cumulus Oncology and in partnership with the Lead discovery Center, Nodus Oncology is developing an innovative portfolio focused on synthetic lethality and collateral vulnerabilities in molecularly defined cancer patient populations Oncology

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Personalized cancer patient treatment that targets metastasis. Personalized cancer patient treatment that targets metastasis. We can treat preventatively and create better patient outcome. Metsystem is developing a metastasis-targeting drug screen platform that is capable of predicting the most effective drug for each patient. With an accurate drug screen we can guide treatment and create better patient outcomes​.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The highest-rated breast cancer org in the U.S. We fund research to find a cure in our lifetime. BCRF is the highest-rated breast cancer organization in the U.S. We provide critical funding for cancer research worldwide to fuel advances in tumor biology, genetics, prevention, treatment, metastasis and survivorship. Since our founding in 1993 by Evelyn H. Lauder, BCRF has raised more than half a billion dollars for lifesaving research. Through a unique and streamlined grants program, we seek out the brightest minds in science and medicine and give them the necessary resources to pursue their best ideas. As a result, …

57 similar entities Type: SMB Activities: biotech deeptech

A drug-discovery company focused on oncology, with a unique and powerful combination of expertise that sets us apart. Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I.

Advancing Human Resilience to Radiation. OUR MISSION: Protecting Lives Against Radiation Threats. USIL Therapeutics pioneers breakthrough medical solutions to safeguard people from the dangers of ionizing radiation. Our mission is to transform radiation defense with treatments and potential cures that go beyond symptomatic care, delivering true whole-body protection. Partnering with governments, defense, and energy sectors worldwide, we provide scalable, effective countermeasures that strengthen resilience and global preparedness in the face of nuclear and radiological risks. Radiation Protection and Drug Development

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pharmacoidea Ltd. is a Hungarian biotech company specialized in drug discovery, pharma- and nutraceutical development. PHARMACOIDEA Ltd. is an innovation-driven Hungarian biotech company specializing in drug discovery, pharma- and nutraceutical development, and advanced therapeutic solutions. Our research portfolio spans from next-generation nutraceuticals to molecularly-targeted drug delivery, biomarker discovery, and experimental therapeutics against SARS-CoV-2 infection. Our multidisciplinary team of scientists is dedicated to translating breakthrough research into real-world medical applications, addressing unmet medical needs with cutting-edge molecular pharmacology, and biotechnology tools. Pharmacoidea's proprietary brain delivery technology enables the transport of macromolecular agents across the blood-brain barrier, holding significant promise for Alzheimer’s …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Proprietary drugs in oncology, diabetology, and pain utilizing unique formulations and drug delivery technologies BIOTTS, a Polish-American biotech company, develops proprietary drugs in oncology, diabetology and pain utilizing unique formulations and drug delivery technologies. Biotts scientists have developed a breakthrough technology of universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). The properties of the carrier increase the bioavailability of active substances several times, enabling them to penetrate through the skin into soft tissues and bones. The carrier can be easily modified to obtain targeted action in pathologically changed tissues. Thanks to the system, it is possible to reduce the therapeutic …

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR …

77 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Discovering the true signals of disease to power life-changing medicines. 90% of potential drugs fail, often because they lack the genetic evidence to prove they will work. Sequence Bio is on a mission to change that. By studying the inherited causes of disease, we aim to identify the right drug targets and predictors of disease and treatment response from the start—ensuring transformative medicines reach the people who need them. Biotechnology and Drug Discovery

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Destroying cancer at the speed of light Theralase® Technologies is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. We strive to continuously improve the quality of life for those afflicted with cancer by focusing our research and development on preventing, alleviating and treating diseases. Serving our higher purpose to bring hope for cancer treatments to light. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the …

70 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

148 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Epigenetic silencing platform for tumor recurrence repression At Repron, we are developing an innovative strategy to inhibit the activity of oncogenes at the basis of tumor malignancy through the use of engineered synthetic factors. Oncogenic transcription factors activate thousands of target genes that, regulating processes like cell proliferation and invasiveness, make the cancer cells dangerous. By rational engineering of these factors, we exploit the natural binding ability to deliver repressive activity, instead of activation to their targets. Substituting the domain responsible for the activation with others featuring epigenetic inhibitory capabilities, we obtained Epigenetic Silencer Factors, that, once delivered in the …

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

346 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Earth Therapeutics Ltd is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology. The Blue Earth Therapeutics story begins in 2021, when the company was formed in Oxford, UK as a sister company to Blue Earth Diagnostics Ltd and part of the Bracco family of companies. Bracco Imaging S.p.A. is a world‐leading diagnostic imaging …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We are dedicated to develop novel stem cell therapies to treat chronic diseases At Blue Cell Therapeutics, our mission is to revolutionize the treatment of erectile dysfunction applying Blue Cell therapy, for men with post-(radical) prostatectomy. We are committed to develop an 'off-the-shelf' curative allogenic stem cell therapy for erectile dysfunction with enhanced safety, efficiency, and accessibility. Our cutting-edge research translates fundamental science into practical, life-changing treatments, bridging the gap between scientific discovery and clinical application. Blue Cell Therapeutics aims to establish the golden standard treatment for erectile dysfunction using innovative stem cell therapy. We encourage you to visit our …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Converting cancer to a manageable, chronic condition Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. Inspirna’s lead drug candidate, ompenaclid (RGX-202), is an orally-administered small molecule that targets the CKB/SLC6A8 pathway, which when activated enables the generation of ATP in response to tumor hypoxia. Ompenaclid is currently being tested in multiple mid-stage clinical trials in patients with advanced or metastatic RAS mutant colorectal cancer. Inspirna’s second clinical stage drug candidate, abequolixron (RGX-104), is an oral small molecule activator of LXR/APOE …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building multi-target botanical drugs for inflammation and neurological diseases. Canurta Therapeutics is a biotechnology company discovering and bioprocessing rare, multipotent polyphenols to find new ways to reverse the chronic disease crisis with botanical therapeutics. With our advanced technologies, Canurta can capture, purify, and enrich rare polyphenols for the first time to target inflammation and address unmet needs in neurology, virology and oncology.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Developing Drugs that Target Individual Caspases to Fight Dementia and Inflammatory Diseases IPCure is a pioneering biotech start-up dedicated to developing innovative treatments for neurodegenerative, metabolic, and inflammatory diseases. Our mission is to enhance the quality of life for patients worldwide by delivering groundbreaking treatments and paving the way towards curing these diseases. IPCURE's expertise lies in targeting individual caspases to develop solutions addressing neurodegenerative and inflammatory diseases. Through cutting-edge research and drug design, we aim to selectively target individual caspases, especially Caspase-2, to create effective therapeutic solutions. Our Flagship drug candidate targets Caspase-2, a crucial enzyme in memory function, …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical stage biotechnology company developing ground-breaking therapies for cardio-renal disease. At Corvidia Therapeutics, we are creating precision therapies by using the science of genomics in new ways. Through random genetic mutation, nature conducts experiments, subtly changing how key proteins work in our bodies and influencing the factors that drive diseases differently in different groups of patients. We study the networks of these genetic variations and how they affect specific diseases in specific patients, allowing us to understand how a personalized drug in complex diseases may behave before we ever begin a clinical trial. We believe that by leveraging the …

73 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Harnessing the Power of Epigenetic Editing Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease. Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression. *Note: Be aware of fraudulent recruiting advertisements and scams: …

90 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies. Apollomics is an innovative biotechnology company committed to the discovery and development of oncology combination therapies. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West. Since our founding in 2015, under the leadership of our experienced management team with in-depth knowledge and expertise of the evolving cancer treatment landscape, we have built a pipeline of ten (10) drug candidates …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel oncolytic immunotherapies. We imagine a world where cancer is a curable disease.

59 similar entities Type: Startup Activities: biotech deeptech

At Shorla Oncology we develop and commercialize innovative oncology medicines for women’s and pediatric cancers. At Shorla Oncology we develop and commercialize innovative oncology drugs. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla’s world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical …

69 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Breakthrough safe and effective therapies for neuropsychiatric disorders Synendos Therapeutics AG is a biopharmaceutical company founded in April 2019 as a spin-off of the University of Bern. Synendos develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate a new drug target (not yet published). The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds which was followed by a thorough med chem programme in collaboration with a CRO. The inhibitors act with a new mechanism of action that enables restoration of the natural function of …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

515 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Next-Generation Synthetic Macrocycle Drug Discovery Our mission is to unlock drug discovery for challenging and currently undruggable pharmaceutical targets, which leave many diseases without effective treatments. The Pure-DEL platform enables, for the first time, the evaluation of billions of synthetic macrocycles with drug-like properties in a single experiment, with the goal of unlocking new disease targets and enabling orally available medicines. * Pure-DEL Technology: https://doi.org/10.1126/science.adn3412 * ETH News Article: https://ethz.ch/en/news-and-events/eth-news/news/2024/09/new-pharmaceutically-active-substances-from-billions-of-newly-combined-molecules.html * Drug Target Review: https://www.drugtargetreview.com/article/153843/unlocking-a-new-molecular-space-in-rapid-drug-discovery/ Drug discovery, DNA-Encoded Libraries, Macrocycles, 'Undruggable' Targets, Oral drug discovery, and Intracellular Targets

63 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology